IDH1 and glioma: Other pan-FGFR inhibitors are being evaluated in different solid tumors such as futibatinib, derazantinib, and rogaratinib, although no data are yet available on their safety or efficacy in gliomas.22,23 Given the growing recognition of FGFR fusions as an important target in IDH-WT GBs, recently the EANO Guideline on targeted treatments recommended to “consider” treatment with FGFR inhibitors in these tumors, although, due to the limited evidence to date, to do so preferably within a clinical trial or within a prospective registry.24